• Users Online: 488
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Reader Login
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Citation statistics : Table of Contents
   2017| July-December  | Volume 3 | Issue 2  
    Online since December 28, 2017

 
 
  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
 
Show all abstracts  Show selected abstracts  Export selected to
  Cited Viewed PDF
VIVA VOCE
Rituximab in the treatment of skin diseases
Murlidhar Rajagopalan, Resham Vasani
July-December 2017, 3(2):105-109
DOI:10.4103/ijdd.ijdd_31_17  
  1 2,837 349
BRIEF REPORT
Successful use of propranolol in infantile hemangiomas
Rajendra Saoji, Manasi Shirolikar
July-December 2017, 3(2):77-80
DOI:10.4103/ijdd.ijdd_35_17  
  - 1,337 115
CASE REPORTS
Intralesional tranexamic acid: Safe and effective way of treatment for melasma
Vani Veggalam, Nataraj Perumalla
July-December 2017, 3(2):81-83
DOI:10.4103/ijdd.ijdd_24_17  
  - 6,501 334
Squamous cell carcinoma in a psoriasis patient possibly due to long-term methotrexate
Guneet Awal, Manpreet Kaur, Ravika Kanish Budhiraja
July-December 2017, 3(2):84-86
DOI:10.4103/ijdd.ijdd_6_17  
  - 767 39
Topical steroid-dependent face: Response to xylometazoline topical
Sushil Kakkar, Prafulla K Sharma
July-December 2017, 3(2):87-89
DOI:10.4103/ijdd.ijdd_6_16  
  - 4,467 158
A case of type 1 pachyonychia congenita with response to acitretin
Bhagyashree Babanrao Supekar, Kinjal Deepak Rambhia, Jayesh Ishwardas Mukhi, Rajesh Pratap Singh
July-December 2017, 3(2):90-92
DOI:10.4103/ijdd.ijdd_28_17  
  - 519 53
EDITORIAL
Tranexamic acid in melasma: Why and how?
Shuken Dashore, Katyain Mishra
July-December 2017, 3(2):61-63
DOI:10.4103/ijdd.ijdd_37_17  
  - 30,659 865
LETTERS TO EDITOR
Imatinib-induced lichen planus resolving with depigmentation
Vrutika Hasmukh Shah, Kinjal Deepak Rambhia, Jayesh Mukhi, Rajesh P Singh
July-December 2017, 3(2):93-94
DOI:10.4103/ijdd.ijdd_25_17  
  - 387 47
Brimonidine “Rebound:” Worsening of rosacea following topical application of brimonidine gel
Sujata Mehta Ambalal
July-December 2017, 3(2):94-96
DOI:10.4103/ijdd.ijdd_18_17  
  - 5,463 82
A case of pediatric cutaneous mastocytosis successfully treated with imatinib mesylate
Rameshwar Gutte, Bhushan Madke, Ashish Bakshi
July-December 2017, 3(2):96-97
DOI:10.4103/ijdd.ijdd_16_17  
  - 970 57
MANAGING A SIDE-EFFECT
Prevention and management of thalidomide toxicity
Bhavana Ravindra Doshi, Nagbhushan Shreyans Chougule, BS Manjunathswamy
July-December 2017, 3(2):100-104
DOI:10.4103/ijdd.ijdd_38_17  
  - 1,159 120
ORIGINAL ARTICLES
A study of fixed-drug reactions at a rural-based tertiary care center, Gujarat
Rita V Vora, Rochit R Singhal, Rahulkrishna S Kota, Bharat M Gajjar
July-December 2017, 3(2):69-72
DOI:10.4103/ijdd.ijdd_33_16  
  - 883 90
Intralesional bleomycin in the treatment of common warts
Mahesh Unni, Vaibhav Tapare
July-December 2017, 3(2):73-76
DOI:10.4103/ijdd.ijdd_26_17  
  - 3,601 207
REVIEW ARTICLE
Bepotastine besilate: A novel anti-histamine
Kiran Godse, Neeti Kumari
July-December 2017, 3(2):64-68
DOI:10.4103/ijdd.ijdd_22_17  
  - 8,764 579
TABLE
Erythroderma: How to know if it is drug induced?
Sudip Das, Nidhi Sharma
July-December 2017, 3(2):98-99
DOI:10.4103/ijdd.ijdd_39_17  
  - 1,985 243
WHATS IN NEWS
News from regulatory corner: Safety communication and recent drug approvals
Shuken Dashore
July-December 2017, 3(2):110-111
DOI:10.4103/2455-3972.221749  
  - 524 60